Journal
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Volume 8, Issue 1, Pages 96-105Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/adt.2009.0217
Keywords
-
Funding
- Department of Lead Identification
- Factor Foundation
- NIGMS [P50 GM067041]
- NIH [U54MH084512]
Ask authors/readers for more resources
Binding of hepatitis C virus (HCV) RNA to core, the capsid protein, results in the formation of the nucleocapsid, the first step in the assembly of the viral particle. A novel assay was developed to discover small molecule inhibitors of core dimerization. This assay is based on time-resolved fluorescence resonance energy transfer (TR-FRET) between anti-tag antibodies labeled with either europium cryptate (Eu) or allophycocyanin (XL-665). The N-terminal 106-residue portion of core protein (core106) was tagged with either glutathione-S-transferase (GST) or a Flag peptide. Tag-free core106 was selected as the reference inhibitor. The assay was used to screen the library of pharmacologically active compounds (LOPAC) consisting of 1,280 compounds and a 2,240-compound library from the Center for Chemical Methodology and Library Development at Boston University (CMLD-BU). Ten of the 28 hits from the primary TR-FRET run were confirmed in a secondary amplified luminescent proximity homogeneous assay (ALPHA screen). One hit was further characterized by dose-response analysis yielding an IC50 of 9.3 mu M. This 513 Da compound was shown to inhibit HCV production in cultured hepatoma cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available